ALX Oncology Exchanges 13.35M Shares for Pre-Funded Warrants
ALX Oncology Holdings Inc. announced it has entered into privately-negotiated exchange agreements with certain stockholders. Under these agreements, stockholders will surrender an aggregate of 13,353,384 shares of common stock to the company. In return, ALX Oncology will issue pre-funded warrants to purchase an aggregate of 13,353,384 shares of common stock. The exchange involves significant stockholders including funds affiliated with Blackstone Annex Master Fund L.P., RA Capital Healthcare Fund, L.P., and venBio Global Strategic Fund, L.P. The transaction is being conducted in reliance on an exemption from registration under Section 3(a)(9) of the Securities Act of 1933 and is expected to settle around October 15, 2026.
Key Highlights
- ALX Oncology Holdings Inc. entered into exchange agreements with stockholders to surrender 13,353,384 shares of common stock.
- In exchange for surrendered shares, the company will issue 13,353,384 pre-funded warrants to purchase common stock.
- The exchange involves funds affiliated with Blackstone Annex Master Fund L.P., RA Capital Healthcare Fund, L.P., and venBio Global Strategic Fund, L.P.
- The issuance of pre-funded warrants is made in reliance upon an exemption from registration pursuant to Section 3(a)(9) of the Securities Act of 1933.
- The exchange is set to settle on or about October 15, 2026.
- Pre-funded warrants have an exercise price of $0.001 per share and are subject to beneficial ownership limitations (4.99% or 9.99%).
Price Impact
More from ALXO